- NewAmsterdam Pharma reported third quarter 2026 sales of US$19.16 million and a net loss of US$17.39 million, with basic loss per share from continuing operations at US$0.14, compared with US$0.61 a year earlier.
- The sharp improvement in quarterly loss, even as the nine month net result stayed broadly similar year on year, highlights how NewAmsterdam Pharma’s cost base and revenue traction are starting to interact differently as obicetrapib advances.
- We will examine how NewAmsterdam Pharma’s investment narrative is shaped by this sharp quarterly sales increase and narrower reported loss.
Scan how NewAmsterdam Pharma’s earnings profile compares with other high research spend plays by reviewing the hand picked 20 high quality undiscovered gems in the sector.
NewAmsterdam Pharma Investment Narrative Recap
To own NewAmsterdam Pharma, you need to be comfortable with a late stage biotech that is still loss making and heavily tied to obicetrapib outcomes and commercialization. The sharp third quarter revenue step up to US$19.16 million, alongside a narrower quarterly loss of US$17.39 million, suggests operating leverage is starting to show through.
The analyst consensus narrative on Simply Wall St frames the key catalyst as European Commission decisions on obicetrapib in 2026 and the PREVAIL interim analysis in early 2027. The latest earnings do not change those milestones. The main near term risk remains ongoing operating losses if obicetrapib revenue does not build as expected.
The third quarter 2026 earnings release is the most relevant update. Sales reached US$19.16 million against US$0.35 million a year earlier, while the quarterly loss narrowed to US$17.39 million from US$72.01 million. For nine months, revenue was US$25.91 million and the loss was US$129.97 million, broadly in line with the prior period.
For you as a shareholder or potential investor, this keeps the story anchored in execution. NewAmsterdam Pharma still needs regulatory decisions in Europe and trial readouts such as PREVAIL, REMBRANDT and RUBENS to support a path toward future profitability. Until then, the trade off between funding ongoing losses and potential future obicetrapib cash flows remains the central judgment call.
NewAmsterdam Pharma's narrative projects US$528.0 million revenue and US$81.1 million earnings by 2029. This assumes revenue grows at a very large 320.1% yearly rate and requires earnings to move by about US$340.6 million from current earnings of a US$259.5 million loss.
Uncover how NewAmsterdam Pharma's fair value indicates a 155% potential upside to its current price before the market closes that gap.
Exploring Other Perspectives
One bearish angle on NewAmsterdam Pharma focuses on the risk that PREVAIL’s interim readout underwhelms, with external work suggesting only a 35% to 38% chance of hitting its MACE goal. Those same cautious analysts were only modeling about US$181.0 million of 2029 revenue and US$28.8 million of earnings before this earnings report, so their narrative is far more restrained than consensus. You can use this quarterly update as a chance to compare those more pessimistic assumptions with the new numbers and decide which storyline is closer to your own view.
Explore 4 other NewAmsterdam Pharma fair value estimates, including one that suggests it could be worth just $50.56!
Form Your Own Verdict
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your NewAmsterdam Pharma research is our analysis highlighting 3 key rewards that could impact your investment decision.
- See our latest analysis for NewAmsterdam Pharma. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate NewAmsterdam Pharma's overall financial health at a glance.
Looking For More Ideas Beyond NewAmsterdam Pharma?
If you want to stress test your thesis on NewAmsterdam Pharma, it can help to line it up against other potential opportunities using the Simply Wall St Screener. That way you are not relying on a single story, and can compare risk, balance sheet strength and income potential side by side.
- If capital preservation comes first for you, check out a basket of 29 resilient stocks with low risk scores that may suit a more cautious approach.
- If you want quality at a price that still looks reasonable, scan a curated set of 32 high quality undervalued stocks with stronger fundamentals.
- If steady cash returns matter more than headline growth, review a focused group of 6 dividend fortresses that prioritize income.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com